首页|EGFR和ALK酪氨酸激酶抑制剂治疗非小细胞肺癌的量-效-毒关系研究进展

EGFR和ALK酪氨酸激酶抑制剂治疗非小细胞肺癌的量-效-毒关系研究进展

扫码查看
原文链接
  • 万方数据
靶向治疗是目前治疗非小细胞肺癌（NSCLC）的重要手段之一，酪氨酸激酶抑制剂（TKI）具有疗效高、毒性低的特点，用于基因突变NSCLC患者的精准治疗。常见的基因突变包括编码表皮生长因子受体（EGFR）和间变性淋巴瘤激酶（ALK）的基因。不同患者对TKI的反应存在差异，监测TKI血药浓度可以更好地预测临床结局（疗效/毒性），优化治疗策略。本文检索近10年国内外相关文献，对临床常用的EGFR-TKI和ALK-TKI血药谷浓度与疗效/毒性关系进行了综述。 Targeted therapy is one of the important methods of treatment for non-small cell lung cancer (NSCLC)。 Tyrosine kinase inhibitors (TKIs) have the characteristics of high efficacy and low toxicity， and are used in the precise treatment in NSCLC patients with gene mutation。 Common gene mutations include genes encoding epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK)。 Different patients have different responses to TKIs。 Monitoring the blood concentration of TKIs can help better predict the clinical outcome (efficacy/toxicity) and optimize the treat strategies。 In this paper， the relevant literature at home and abroad in the past 10 years are searched， and the relationship between the blood trough concentration of EGFR-TKI and ALK-TKI commonly used in clinic and the efficacy/toxicity are reviewed。
Research progress on dose-effect-toxicity relationship of EGFR- and ALK-tyrosine kinase inhibitors in the treatment of non-small cell lung cancer
Targeted therapy is one of the important methods of treatment for non-small cell lung cancer (NSCLC). Tyrosine kinase inhibitors (TKIs) have the characteristics of high efficacy and low toxicity, and are used in the precise treatment in NSCLC patients with gene mutation. Common gene mutations include genes encoding epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK). Different patients have different responses to TKIs. Monitoring the blood concentration of TKIs can help better predict the clinical outcome (efficacy/toxicity) and optimize the treat strategies. In this paper, the relevant literature at home and abroad in the past 10 years are searched, and the relationship between the blood trough concentration of EGFR-TKI and ALK-TKI commonly used in clinic and the efficacy/toxicity are reviewed.

Molecular targeted therapyDose-response relationship, drugReceptor, epidermal growth factorAnaplastic lymphoma kinaseTyrosine kinase inhibitorsAdverse drug reaction

裴一涵、李悦、毕云彦、郭楠、张文、李菁锦

展开 >

山东第一医科大学附属省立医院药学部，济南　250021

分子靶向治疗 剂量效应关系,药物 受体,表皮生长因子 间变性淋巴瘤激酶 酪氨酸激酶抑制剂 药物不良反应

国家自然科学基金山东省医学会临床科研项目

82304627YXH2022DZX02006

2024

10.3760/cma.j.cn114015-20231129-00845

药物不良反应杂志
中华医学会

药物不良反应杂志

CSTPCD
影响因子：0.667
ISSN：1008-5734
年,卷(期)：2024.26(3)
  • 48